Skip to main content

Table 3 Means and correlations of IGFBP-3 levels with mammographic breast density

From: Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional study

  Adjusted means of percent density (percentage)a Adjusted means of absolute density (cm2)a,b
Levels of IGFBP-3 Intactc Fragmentedd Totale Intactc Fragmentedd Totale
   Quartile 1 (n = 185) 42.2 45.3 44.5 48.6 48.3 49.4
   Quartile 2 (n = 184) 42.9 44.3 44.7 46.3 48.0 48.6
   Quartile 3 (n = 184) 40.4 40.3 40.7 45.7 45.9 45.0
   Quartile 4 (n = 184) 44.0 39.6 39.6 45.5 43.9 43.1
   rf (P) 0.075 (0.04) -0.171 (< 0.0001) -0.151 (< 0.0001) -0.010 (0.79) -0.092 (0.01) -0.094 (0.01)
   rf (P)a 0.031 (0.40) -0.105 (0.004) -0.095 (0.01) -0.029 (0.43) -0.066 (0.07) -0.075 (0.04)
   rf (P)g 0.022 (0.55) -0.112 (0.003) -0.104 (0.005) -0.042 (0.26) -0.078 (0.04) -0.090 (0.02)
  1. aMeans and correlations are adjusted for age, body mass index, waist-to-hip ratio, alcohol intake, energy intake, physical activity, parity, smoking status, and total IGF-I levels. bMeans of absolute density are presented as back-transformed values; square-root-transformed absolute density is used in the correlation. cQuartiles of intact IGFBP-3 are ≤883.80, 883.81 to 1,021.00, 1,021.01 to 1,170.50, and > 1,170.50 ng/mL. dQuartiles of fragmented IGFBP-3 are ≤3,137.50, 3,137.51 to 3,662.50, 3,662.51 to 4,263.00, and > 4,263.00 ng/mL. eQuartiles of total IGFBP-3 are ≤4,183.0, 4,183.1 to 4,695.0, 4,695.1 to 5,290.0, and > 5,290.0 ng/mL. fPearson correlation between continuous variables; adjusted correlations are partial Pearson coefficients. gCorrelations are adjusted for age, body mass index, waist-to-hip ratio, alcohol intake, energy intake, physical activity, parity, smoking status, total IGF-I levels, age at menarche, number of full-term pregnancies, age at first full-term pregnancy, lactation, family history of breast cancer, number of breast biopsies, education, past use of oral contraceptives, past use of hormone replacement therapy, and height.